RE:RE:RE:RE:Rare and Orphan diseases approved w smaller pt trial numbersPancreatic cancer has the highest mortality rate of all the cancer types—accounting for 3% of all cancer deaths in the United States—and is more common among male patients than female patients. - rates of pancreatic head adenocarcinoma—an especially aggressive and fatal tumor situated at the head of the pancreas—appeared to be increasing.
https://ascopost.com/news/february-2023/pancreatic-cancer-rates-may-be-rising-faster-among-younger-women-patients-than-younger-men/
Pancreatic cancers are hypovascular tumors surrounded by dense desmoplastic tissue, drug resistance may occur as chemotherapeutic agents fail to penetrate the primary tumor.
Pelareorep’s ability to invade the dense desmoplastic tissue surrounding the hypovascular pancreatic cancer, is thus making pelareorep an effective agent against drug resistant tumors. Since the majority of pancreatic cancers have RAS pathway activation, pelareorep cn serve as a promising active agent to overcome this barrier when combined with conventional chemotherapy ( and now in combination with immune checkpoint inhibitors since ONCY's pelareorep is able to overcome and remodel the hypoxic TME in advance of the addition of an ICI)
https://bmccancer.biomedcentral.com/articles/10.1186/s12885-015-1518-0
https://stockhouse.com/companies/bullboard/oncy/oncolytics-biotech-inc?postid=35848743